A rational design of casting machine mold

Metallurgist ◽  
1972 ◽  
Vol 16 (1) ◽  
pp. 20-21
Author(s):  
V. F. Bannykh ◽  
G. A. Mashkov
Metallurgist ◽  
1975 ◽  
Vol 19 (7) ◽  
pp. 498-499
Author(s):  
M. I. Sharapov
Keyword(s):  

2013 ◽  
Vol 787 ◽  
pp. 445-449
Author(s):  
Ao Bing Wang ◽  
Xue Dong Wang ◽  
Zheng Dong Chen ◽  
Li Yong Ni ◽  
Xiao Qin Gu

The structure and processing of double chamber throttle valve body castings were analyzed. Die-casting molding process scheme was established. The design of mold includes three core-drawing mechanisms. Considering the large parts surface area and the relatively small wall thickness and the requirement of parting, the gate was arranged on the casting bottom surface. For economy and die easy maintenance considerations, die-casting machine, mold, and mold standard parts should be standard parts. The designs of mold gating system and non-standard pieces were completed. Proved by actual production, the mold operated smoothly, without clamping stagnation, and the production of die castings meet delivery requirements.


2013 ◽  
Vol 378 ◽  
pp. 350-354
Author(s):  
Xue Dong Wang ◽  
Jian He Lin ◽  
Suo Qing Yu ◽  
Li Yong Ni

The structure and processing of car holders castings were analyzed. Die-casting molding process scheme was established. The design of mold includes three core-drawing mechanisms. the gate of the gating system was arranged on the casting bottom surface. For economy and die easy maintenance considerations, die-casting machine, mold, and mold standard parts should be standard parts. The designs of mold gating system and non-standard pieces were completed with the aid of PROE. Proved by actual production, the mold operated smoothly, without clamping stagnation, and the production of die castings meet delivery requirements.


2019 ◽  
Vol 24 (1) ◽  
pp. 35-41
Author(s):  
Viktor Oleksandrovich Didenko ◽  
Yuliia Valeriivna Bondarenko ◽  
Ievhen Volodymyrovych Verbytskyi ◽  
Oleksandr Fedorovych Bondarenko

2021 ◽  
Vol 23 (1) ◽  
pp. 219-228
Author(s):  
Nabanita Saikia ◽  
Mohamed Taha ◽  
Ravindra Pandey

The rational design of self-assembled nanobio-molecular hybrids of peptide nucleic acids with single-wall nanotubes rely on understanding how biomolecules recognize and mediate intermolecular interactions with the nanomaterial's surface.


2020 ◽  
Vol 8 (35) ◽  
pp. 18207-18214
Author(s):  
Dongbo Jia ◽  
Lili Han ◽  
Ying Li ◽  
Wenjun He ◽  
Caichi Liu ◽  
...  

A novel, rational design for porous S-vacancy nickel sulfide catalysts with remarkable catalytic performance for alkaline HER.


Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
ES Halldorsdottir ◽  
S Oddsson ◽  
AM Einarsdottir ◽  
B Eiriksdottir ◽  
NM Kowal ◽  
...  

1993 ◽  
Vol 69 (02) ◽  
pp. 157-163 ◽  
Author(s):  
Irving Fox ◽  
Adrian Dawson ◽  
Peter Loynds ◽  
Jane Eisner ◽  
Kathleen Findlen ◽  
...  

SummaryHirulog™ (BG8967) is a direct thrombin inhibitor built by rational design using the protein hirudin as a model (Maraganore et al. [1990]; Biochemistry 29: 7095–101). In order to evaluate the therapeutic potential for hirulog in the management of thrombotic disease, the tolerability and anticoagulant activity of the agent were examined in a study of human volunteers.In a randomized, placebo-controlled study (n = 54), the intravenous infusion of hirulog over 15 min showed a rapid, dose-dependent prolongation of activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). There was a corresponding dose-dependent increase in plasma hirulog levels. The peptide was rapidly cleared with a half-life of 36 min and a total body clearance rate for the peptide of 0.43 1 kg−1 h−1. Similar activity was observed following subcutaneous injection but with sustained pharmacodynamic and pharmacokinetic behavior. There was a significant correlation between pharmacokinetic and pharmacodynamic variables for both intravenous (r = 0.8, p <0.001) and subcutaneous administration (r = 0.7, p = 0.002).To evaluate the possible interactions of aspirin on the tolerability and anticoagulant activity of intravenous hirulog, a cross-over design was employed in eight subjects. Aspirin administration did not modify the peptide’s activity. At the administered dose of 0.6 mg kg−1 h−1 for 2 h, hirulog infusion prolonged APTT from 230 to 260% baseline. The infusion of hirulog in subjects who had received aspirin was not associated with any significant changes in the template bleeding time.The final phase of the study examined the activity and tolerability of hirulog in ten subjects during prolonged intravenous infusions for up to 24 h. The peptide (0.3 mg kg−1 h−1) exhibited sustained anticoagulant activity with no evidence for a cumulative effect. During hirulog infusion, APTT was prolonged from 210 to 250% baseline.In all phases of the study, hirulog administration was generally well-tolerated.Our observations show that hirulog is an active antithrombin agent with excellent tolerability in humans. As a direct thrombin inhibitor, hirulog provides a novel approach for the management of thrombotic disease.


Sign in / Sign up

Export Citation Format

Share Document